Home
About
Overview
Sharing Data
ORCID
Help
History (2)
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Supplementing cross-cover communication with the patient acuity rating.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Supplementing cross-cover communication with the patient acuity rating.
Supplementing cross-cover communication with the patient acuity rating. J Gen Intern Med. 2013 Mar; 28(3):406-11.
View in:
PubMed
subject areas
Attitude of Health Personnel
Clinical Competence
Communication
Cross-Sectional Studies
Decision Making
Education, Medical, Graduate
Educational Measurement
Female
Hospitals, Teaching
Humans
Illinois
Internal Medicine
Internship and Residency
Male
Patient Acuity
Patient Handoff
authors with profiles
James Woodruff
Dana Edelson
Vineet Arora